Advertisement

Diagnosis and Prognostic Factors of UTUC

  • Bum Sik Tae
  • Chang Wook Jeong
Chapter

Abstract

Preoperative tumor staging and diagnosis are difficult with currently available imaging modalities, but clinical variables have been identified to enable risk stratification and distinguish high-risk and low-risk tumors (Baard et al., Nat Rev Urol 14:181–191, 2017). The EAU and Société International d’Urologie (SIU)–International Consultation on Urological Diseases (ICUD) recommendations for imaging in UTUC diagnosis include urography using CT (CTU) or urography using MRI (Baard et al., Nat Rev Urol 14:181–191, 2017). In the standard diagnostic work-up, urine cytology and a cystoscopy are usually recommended to rule out a concomitant bladder tumor. In addition, diagnostic ureterorenoscopy and biopsy are recommended in patients in whom the findings of these procedures could influence treatment decisions, between radical nephroureterectomy and kidney-sparing treatment.

Keywords

Upper urothelial carcinoma Diagnosis Imaging Prognostic factor 

References

  1. 1.
    Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73:111.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998;52:594–601.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Geerdsen J. Tumours of the renal pelvis and ureter. Symptomatology, diagnosis, treatment and prognosis. Scand J Urol Nephrol. 1979;13:287–90.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012;188:2473–81.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Linder BJ, Bass EJ, Mostafid H, Boorjian SA. Guideline of guidelines: asymptomatic microscopic haematuria. BJU Int. 2018;121:176.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Liang C, Wang J, Liu H, Huang L, Xu D, Qian S, et al. Preoperative pyuria predicts advanced pathologic tumor stage and worse survival in patients with urothelial carcinoma of the upper urinary tract treated by radical nephroureterectomy. Urol Oncol. 2016;34:418.e1–7.CrossRefGoogle Scholar
  7. 7.
    Messer J, Shariat SF, Brien JC, Herman MP, Ng CK, Scherr DS, et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011;108:701–5.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol. 2001;165:600–11.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Brien JC, Shariat SF, Herman MP, Ng CK, Scherr DS, Scoll B, et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol. 2010;184:69–73.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Hurel S, Roupret M, Seisen T, Comperat E, Phe V, Droupy S, et al. Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. World J Urol. 2015;33:335–41.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Luo B, Li W, Deng CH, Zheng FF, Sun XZ, Wang DH, et al. Utility of fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma. Cancer Genet Cytogenet. 2009;189:93–7.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Baard J, de Bruin DM, Zondervan PJ, Kamphuis G, de la Rosette J, Laguna MP. Diagnostic dilemmas in patients with upper tract urothelial carcinoma. Nat Rev Urol. 2017;14:181–91.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, et al. Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis. Ann Intern Med. 2015;163:922–31.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol. 2013;63:4–15.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Mohapatra A, Vemana G, Bhayani S, Baty J, Vetter J, Strope SA. Trends in the utilization of imaging for upper tract urothelial carcinoma. Urol Oncol. 2016;34:236.e23–8.CrossRefGoogle Scholar
  16. 16.
    McCarron JP, Mills C, Vaughn ED Jr. Tumors of the renal pelvis and ureter: current concepts and management. Semin Urol. 1983;1:75–81.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, et al. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol. 2013;31:904–8.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell-Walsh urology: expert consult premium edition: enhanced online features and print, 4-volume set. Amsterdam: Elsevier Health Sciences; 2011.Google Scholar
  19. 19.
    Murphy DM, Zincke H, Furlow WL. Management of high grade transitional cell cancer of the upper urinary tract. J Urol. 1981;125:25–9.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Murphy DM, Zincke H, Furlow WL. Primary grade 1 transitional cell carcinoma of the renal pelvis and ureter. J Urol. 1980;123:629–31.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Jung P, Brauers A, Nolte-Ernsting CA, Jakse G, Gunther RW. Magnetic resonance urography enhanced by gadolinium and diuretics: a comparison with conventional urography in diagnosing the cause of ureteric obstruction. BJU Int. 2000;86:960–5.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Chen GL, El-Gabry EA, Bagley DH. Surveillance of upper urinary tract transitional cell carcinoma: the role of ureteroscopy, retrograde pyelography, cytology and urinalysis. J Urol. 2000;164:1901–4.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Bergman H, Friedenberg RM, Sayegh V. Carcinoma of the ureter: clinical report of seven cases. J Urol. 1962;87:119–21.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Kobayashi H, Ide H, et al. Metastatic behavior of upper tract urothelial carcinoma after radical nephroureterectomy: association with primary tumor location. Ann Surg Oncol. 2014;21:1038–45.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Streem SB, Pontes JE, Novick AC, Montie JE. Ureteropyeloscopy in the evaluation of upper tract filling defects. J Urol. 1986;136:383–5.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Kang CH, Yu TJ, Hsieh HH, Yang JW, Shu K, Huang CC, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer. 2003;98:1620–6.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Sung HH, Jeon HG, Han DH, Jeong BC, Seo SI, Lee HM, et al. Diagnostic ureterorenoscopy is associated with increased intravesical recurrence following radical nephroureterectomy in upper tract urothelial carcinoma. PLoS One. 2015;10:e0139976.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Luo HL, Kang CH, Chen YT, Chuang YC, Lee WC, Cheng YT, et al. Diagnostic ureteroscopy independently correlates with intravesical recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Ann Surg Oncol. 2013;20:3121–6.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Xylinas E, Kluth L, Passoni N, Trinh QD, Rieken M, Lee RK, et al. Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. Eur Urol. 2014;65:650–8.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Lee JK, Kim KB, Park YH, Oh JJ, Lee S, Jeong CW, et al. Correlation between the timing of diagnostic ureteroscopy and intravesical recurrence in upper tract urothelial cancer. Clin Genitourin Cancer. 2016;14:e37–41.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Huang A, Low RK, deVere WR. Nephrostomy tract tumor seeding following percutaneous manipulation of a ureteral carcinoma. J Urol. 1995;153:1041–2.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Kim HS, Jeong CW, Kwak C, Kim HH, Ku JH. Association between demographic factors and prognosis in urothelial carcinoma of the upper urinary tract: a systematic review and meta-analysis. Oncotarget. 2017;8:7464–76.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Rink M, Xylinas E, Margulis V, Cha EK, Ehdaie B, Raman JD, et al. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol. 2013;63:1082–90.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012;62:100–14.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Yafi FA, Novara G, Shariat SF, Gupta A, Matsumoto K, Walton TJ, et al. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int. 2012;110:E7–13.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Ouzzane A, Colin P, Xylinas E, Pignot G, Ariane MM, Saint F, et al. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol. 2011;60:1258–65.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Chromecki TF, Cha EK, Fajkovic H, Margulis V, Novara G, Scherr DS, et al. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol. 2012;61:245–53.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Park J, Ha SH, Min GE, Song C, Hong B, Hong JH, et al. The protective role of renal parenchyma as a barrier to local tumor spread of upper tract transitional cell carcinoma and its impact on patient survival. J Urol. 2009;182:894–9.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Lee JN, Kwon SY, Choi GS, Kim HT, Kim TH, Kwon TG, et al. Impact of surgical wait time on oncologic outcomes in upper urinary tract urothelial carcinoma. J Surg Oncol. 2014;110:468–75.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Guarnizo E, Pavlovich CP, Seiba M, Carlson DL, Vaughan ED Jr, Sosa RE. Ureteroscopic biopsy of upper tract urothelial carcinoma: improved diagnostic accuracy and histopathological considerations using a multi-biopsy approach. J Urol. 2000;163:52–5.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Mullerad M, Russo P, Golijanin D, Chen HN, Tsai HH, Donat SM, et al. Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. J Urol. 2004;172:2177–81.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Novara G, De Marco V, Gottardo F, Dalpiaz O, Bouygues V, Galfano A, et al. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer. 2007;110:1715–22.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Lane BR, Smith AK, Larson BT, Gong MC, Campbell SC, Raghavan D, et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer. 2010;116:2967–73.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Yu HS, Hwang JE, Chung HS, Cho YH, Kim MS, Chang Hwang E, et al. Is preoperative chronic kidney disease status associated with oncologic outcomes in upper urinary tract urothelial carcinoma? A multicenter propensity score-matched analysis. Oncotarget. 2017;8:66540–9.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Ehdaie B, Chromecki TF, Lee RK, Lotan Y, Margulis V, Karakiewicz PI, et al. Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma. J Urol. 2011;186:66–72.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Dalpiaz O, Pichler M, Mannweiler S, Martin Hernandez JM, Stojakovic T, Pummer K, et al. Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. Br J Cancer. 2014;110:2531–6.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Kang M, Jeong CW, Kwak C, Kim HH, Ku JH. Prognostic role of neutrophil-to-lymphocyte ratio-based markers during pre- and postadjuvant chemotherapy in patients with advanced urothelial carcinoma of upper urinary tract. Clin Genitourin Cancer. 2017;15:e633–e43.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Lopez-Beltran A, Bassi P, Pavone-Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol. 2004;45:257–66.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Soukup V, Capoun O, Cohen D, Hernandez V, Babjuk M, Burger M, et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization grading classification systems in non-muscle-invasive bladder cancer: a European Association of Urology non-muscle invasive bladder cancer guidelines panel systematic review. Eur Urol. 2017;72:801–13.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Li WM, Li CC, Ke HL, Wu WJ, Huang CN, Huang CH. The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy. J Urol. 2009;182:451–8; discussion 8.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Li CC, Chang TH, Wu WJ, Ke HL, Huang SP, Tsai PC, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008;54:1127–34.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115:1224–33.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Wheat JC, Weizer AZ, Wolf JS Jr, Lotan Y, Remzi M, Margulis V, et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urol Oncol. 2012;30:252–8.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Otto W, Shariat SF, Fritsche HM, Gupta A, Matsumoto K, Kassouf W, et al. Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. World J Urol. 2011;29:487–94.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Kondo T, Hashimoto Y, Kobayashi H, Iizuka J, Nakazawa H, Ito F, et al. Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: impact on patient survival. Int J Urol. 2010;17:848–54.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Kondo T, Nakazawa H, Ito F, Hashimoto Y, Toma H, Tanabe K. Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol. 2007;178:1212–7; discussion 7.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Colin P, Ouzzane A, Yates DR, Audenet F, Pignot G, Arvin-Berod A, et al. Influence of positive surgical margin status after radical nephroureterectomy on upper urinary tract urothelial carcinoma survival. Ann Surg Oncol. 2012;19:3613–20.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, et al. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm? BJU Int. 2006;98:1176–80.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Keeley FX, Kulp DA, Bibbo M, McCue PA, Bagley DH. Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma. J Urol. 1997;157:33–7.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Rey A, Lara PC, Redondo E, Valdes E, Apolinario R. Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter. Relation to tumor proliferation and survival. Cancer. 1997;79:2178–85.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Hashimoto H, Sue Y, Saga Y, Tokumitsu M, Yachiku S. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter. Int J Urol. 2000;7:457–63.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology. 2004;63:1079–83.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Jeon HG, Jeong IG, Bae J, Lee JW, Won JK, Paik JH, et al. Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. Urology. 2010;76:513.e7–12.Google Scholar
  64. 64.
    Joung JY, Yang SO, Jeong IG, Han KS, Seo HK, Chung J, et al. Identification of immunohistochemical factors that predict the synchronous or metachronous development of bladder tumors in patients with upper urinary tract tumors. Urol Int. 2008;81:306–11.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Ahn C, Jeong CW, Kwak C, Kim HH, Kim HS, Ku JH. Ki-67 as a prognostic marker in upper urinary tract urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer. 2018;16:e831.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Leibl S, Zigeuner R, Hutterer G, Chromecki T, Rehak P, Langner C. EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. APMIS. 2008;116:27–32.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Long X, Zu X, Li Y, He W, Hu X, Tong S, et al. Epidermal growth factor receptor and Ki-67 as predictive biomarkers identify patients who will be more sensitive to intravesical instillations for the prevention of bladder cancer recurrence after radical nephroureterectomy. PLoS One. 2016;11:e0166884.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65:3756–88.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Kashibuchi K, Tomita K, Schalken JA, Kume H, Yamaguchi T, Muto S, et al. The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. Eur Urol. 2006;49:839–45; discussion 45.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Fromont G, Roupret M, Amira N, Sibony M, Vallancien G, Validire P, et al. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol. 2005;48:764–70.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Nakanishi K, Kawai T, Torikata C, Aurues T, Ikeda T. E-cadherin expression in upper-urinary-tract carcinoma. Int J Cancer. 1997;74:446–9.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Ke HL, Li WM, Lin HH, Hsu WC, Hsu YL, Chang LL, et al. Hypoxia-regulated microRNA-210 overexpression is associated with tumor development and progression in upper tract urothelial carcinoma. Int J Med Sci. 2017;14:578–84.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Izquierdo L, Truan D, Petit A, Gutierrez R, Mallofre C, Alcaraz A. Adhesion molecules alpha, beta and gamma-catenin as prognostic factors of tumour progression in upper urinary tract urothelial tumours: the role of AKT-P/GSK-3beta/beta-catenin pathway. BJU Int. 2009;104:100–6.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Wu CF, Ng KF, Chen CS, Chang PL, Chuang CK, Weng WH, et al. Expression of parvin-beta is a prognostic factor for patients with urothelial cell carcinoma of the upper urinary tract. Br J Cancer. 2010;103:852–60.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Winkler A, Zigeuner R, Rehak P, Hutterer G, Chromecki T, Langner C. CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. Virchows Arch. 2007;450:59–64.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Ohtsuka Y, Kawakami S, Fujii Y, Koga F, Saito K, Ando N, et al. Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract. BJU Int. 2006;97:1322–6.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Kosaka T, Kikuchi E, Mikami S, Miyajima A, Shirotake S, Ishida M, et al. Expression of snail in upper urinary tract urothelial carcinoma: prognostic significance and implications for tumor invasion. Clin Cancer Res. 2010;16:5814–23.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Nakanishi K, Tominaga S, Hiroi S, Kawai T, Aida S, Kasamatsu H, et al. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch. 2002;441:559–63.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Jeong IG, Kim SH, Jeon HG, Kim BH, Moon KC, Lee SE, et al. Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract. Hum Pathol. 2009;40:668–77.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Nakanishi K, Kawai T, Hiroi S, Kumaki F, Torikata C, Aurues T, et al. Expression of telomerase mRNA component (hTR) in transitional cell carcinoma of the upper urinary tract. Cancer. 1999;86:2109–16.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Inoue K, Kamada M, Slaton JW, Fukata S, Yoshikawa C, Tamboli P, et al. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res. 2002;8:1863–70.PubMedPubMedCentralGoogle Scholar
  82. 82.
    Miyata Y, Kanda S, Nomata K, Hayashida Y, Kanetake H. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival. Urology. 2004;63:602–8.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Saito K, Kawakami S, Ohtsuka Y, Fujii Y, Masuda H, Kumagai J, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 2007;100:269–73.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, et al. Impact of combined use of blood-based inflammatory markers on patients with upper tract urothelial carcinoma following radical nephroureterectomy: proposal of a cumulative marker score as a novel predictive tool for prognosis. Eur Urol Focus. 2015;1:54–63.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Lehmann J, Suttmann H, Kovac I, Hack M, Kamradt J, Siemer S, et al. Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. Eur Urol. 2007;51:1281–8.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Suyama T, Nakajima K, Kanbe S, Tanaka N, Hara H, Ishii N. Prognostic significance of preoperative serum CYFRA 21-1 in patients with upper urinary tract urothelial carcinoma. Int J Urol. 2011;18:43–7.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Roupret M, Fromont G, Azzouzi AR, Catto JW, Vallancien G, Hamdy FC, et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology. 2005;65:1233–7.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005;23:2903–10.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M, et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009;55:650–7.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Korea University College of MedicineSeoulSouth Korea
  2. 2.Department UrologyKorea University Ansan HospitalAnsanSouth Korea
  3. 3.Department UrologySeoul National University HospitalSeoulSouth Korea

Personalised recommendations